Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.36 |
| ▸ | SGK1 | O00141 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 4/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.33 |
| ▸ | RORA | P35398 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20680929 | 0.89 | NMT1 (0.36) | BRD4CHRM2CHRM1RRM1RRM2B | |
| SCHEMBL22015029 | 0.81 | ALPL (0.47) | ALPLSMN1; SMN2 | |
| SCHEMBL24978417 | 0.77 | ALDH1A1 (0.43) | HSD11B1RORASMN1; SMN2 | |
| SCHEMBL20914739 | 0.77 | POLB (0.39) | BRD4PTK2BHSD11B1SMN1; SMN2 | |
| SCHEMBL25067022 | 0.75 | NLRP3 (0.46) | RORASMN1; SMN2 | |
| SCHEMBL24592562 | 0.75 | HSD11B1 (0.40) | HSD11B1TNKSPARP1TNKS2 | |
| SCHEMBL24978776 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL22012922 | 0.74 | PSEN1 (0.32) | HSD11B1RORASMN1; SMN2 | |
| SCHEMBL22013636 | 0.74 | NMT1 (0.52) | CHRM2CHRM1RRM1RRM2BALPL | |
| SCHEMBL29927210 | 0.73 | HSD11B1 (0.39) | HSD11B1TNKSPARP1TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | BRD4 1078/4885PTK2B 3948/4885SGK1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.